NASDAQ · BJDX
Healthcare · Medical - Devices
$1.05
Up+$0.01 (+0.95%)
Updated Aug 13, 2026, 8:09 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BJDX closed at $1.05 after 21 trading sessions, down 22.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $1.03 | $1.10 | $1.0062 | $1.05 | 315.06K |
| Aug 11, 2026 | $0.9935 | $1.08 | $0.95 | $1.07 | 761.14K |
| Aug 10, 2026 | $1.05 | $1.07 | $0.9555 | $0.9872 | 846.86K |
| Aug 7, 2026 | $1.15 | $1.15 | $1.05 | $1.07 | 760.68K |
| Aug 6, 2026 | $1.12 | $1.2595 | $1.0507 | $1.15 | 3.22M |
| Aug 5, 2026 | $1.48 | $1.69 | $1.23 | $1.24 | 90.61M |
| Aug 4, 2026 | $0.9093 | $1.04 | $0.9093 | $1.00 | 23.37M |
| Aug 3, 2026 | $0.863 | $0.9959 | $0.86 | $0.9423 | 444.54K |
| Jul 31, 2026 | $0.95 | $0.95 | $0.86 | $0.86 | 111.64K |
| Jul 30, 2026 | $0.878 | $0.9476 | $0.83 | $0.9293 | 192.18K |
| Jul 29, 2026 | $0.9901 | $0.9999 | $0.8341 | $0.8786 | 258.23K |
| Jul 28, 2026 | $1.05 | $1.06 | $0.96 | $1.00 | 284.95K |
| Jul 27, 2026 | $1.05 | $1.11 | $1.02 | $1.10 | 366.21K |
| Jul 24, 2026 | $1.13 | $1.13 | $1.02 | $1.03 | 249.94K |
| Jul 23, 2026 | $1.15 | $1.17 | $1.1087 | $1.14 | 257.06K |
| Jul 22, 2026 | $1.07 | $1.17 | $1.03 | $1.15 | 719.49K |
| Jul 21, 2026 | $1.15 | $1.17 | $1.12 | $1.16 | 1.07M |
| Jul 20, 2026 | $1.28 | $1.34 | $1.21 | $1.21 | 748.27K |
| Jul 17, 2026 | $1.30 | $1.47 | $1.255 | $1.45 | 1.55M |
| Jul 16, 2026 | $1.31 | $1.33 | $1.25 | $1.30 | 894.81K |
| Jul 15, 2026 | $1.27 | $1.39 | $1.26 | $1.35 | 4.3M |
The latest Smart Investors Daily articles mentioning BJDX.
BJDX research
Company profile and research snapshot.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2023 | Dawson James | Neutral | — |
| Jan 12, 2022 | Dawson James | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 21, 2026
Bluejay Diagnostics, Inc. (NASDAQ:BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the successful completion of patient enrollment in its
Benzinga · Jul 20, 2026
Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares
Benzinga · Jul 17, 2026
Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-market session. The market value of their outstanding shares is at $5.1 million. Advanced Biomed (NASDAQ:ADVB) shares
Benzinga · Mar 6, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BJDX.
